FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
Lotimatou avorago bare								
hours per response:	0.5							
p soponoo.	0.0							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  GERAGHTY JAMES A					IDE	2. Issuer Name and Ticker or Trading Symbol  IDERA PHARMACEUTICALS, INC. [ IDRA ]									ck all app	olicable) ctor	10%	Person(s) to Issuer	
					3. Date of Earliest Transaction (Month/Day/Year) 01/02/2014										Offic belo	er (give title w)	Othe belov	r (specify v)	
167 SIDNEY ST.					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) CAMBR	IDGE MA	A 0	2139											2	_	filed by Mor	e Reporting Pe re than One Re		
(City)	(Sta	ate) (Z	Zip)																
		Table	e I - N	on-Deriv	ative S	Secu	ıritie	s Acc	uired, l	Disp	osed o	f, or l	Bene	ficiall	y Own	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/				y/Year)	Execution Date,			3. Transaction Code (Instr. 8)  4. Securities Acquired (Disposed Of (D) (Instr. and 5)					Secur	icially d	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount (A) or (D)			Price	Repoi Trans		(11150: 4)	(IIISU: 4)	
Common Stock 01/02/20				014		A		1,013(	1)	A	\$4.75	75 401,013		D					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Conversion or Exercise Price of Derivative Security  (Instr. 3)  3. Transaction Date Execution Date (Month/Day/Year)  Date Date (Month/Day/Year)  Execution Date, if any (Month/Day/Year)			ion Date,	Code (Ir 8)	5. Number of Orde (Instr. Derivative			6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)  Amoun or Numbe		on D S (I	Price f erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirec (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

## Explanation of Responses:

 $1. \ This \ stock \ was \ issued \ to \ the \ reporting \ person \ pursuant \ to \ the \ Issuer's \ director \ compensation \ program \ in \ lieu \ of \ cash.$ 

## Remarks:

/s/ James A. Geraghty

01/06/2014

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).